However, in the context of a growing population with underlying health conditions and factors predisposing to diabetes at baseline, reliance on medical management with insulin and the off-label usage of glucose-lowering agents/disease-modifying therapies, including glyburide and metformin, has become increasingly common to help manage this condition. The gene discussed is INS; the disease is diabetes mellitus.